Do GLP-1 Drugs Lower Breast Cancer Risk? What a 110,000-Woman Study Really Shows
Researchers at Penn Medicine looked at the health records of more than 110,000 women and found that those with a prescription for a GLP-1 drug, the class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were roughly 30% less likely to be diagnosed with breast cancer than those without one, according to research published in JCO Oncology…
